Neo-Sequence 2：Phase 2 Study of Neoadjuvant Chemotherapy Plus Anti-angiogenesis Therapy and Immunotherapy for Locally Advanced Diffuse Gastric Cancer
The regimen of Albumin paclitaxel+SOX+BEV neoadjuvant therapy lasted for 6 cycles, during which PD-1 monoclonal antibody therapy was interspersed for 4 cycles for locally advanced diffuse gastric cancer.
• Local advanced diffuse or mixed type gastric cancer detected by pathology and endoscopy;
• Chest, abdomen, and pelvis enhanced CT, neck and supraclavicular ultrasound, gastroscopy, and endoscopic ultrasound were used to diagnose T3-4NanyM0 gastric cancer or gastroesophageal junction cancer (refer to AJCC staging, 8th edition);
• Has not received any anti-tumor treatment for gastric cancer yet;
• Age range from 18 to 75 years old;
• ECOG score 0-1 points;
• Liver and kidney function and blood routine meet the following conditions:
• Neutrophils\>1.5G/L, Hb\>90g/L, PLT\>100G/L; ALT and AST\<2.5ULN; TBIL\<1.5 ULN; Cr\<1.0ULN;
• Left ventricular ejection fraction\>60%;
• Good compliance and ability to accept long-term follow-up;
• Sign informed consent.